Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.
The paper follows closely on research published by the same lab in late February that demonstrated how the drug worked against the Middle East Respiratory Syndrome (MERS) virus, a related coronavirus.
“We were optimistic that we would see the same results against the SARS-CoV-2 virus,” said Matthias Götte, chair of medical microbiology and immunology at U of A.
“We obtained almost identical results as we reported previously with MERS, so we see that remdesivir is a very potent inhibitor for coronavirus polymerases.”
Götte’s new paper demonstrates how remdesivir, developed in 2014 to fight the Ebola epidemic, works in detail. He likens the polymerase to the engine of the virus, responsible for synthesizing the virus’ genome.
“If you target the polymerase, the virus cannot spread, so it’s a very logical target for treatment,” Götte said.
The lab’s work shows how remdesivir tricks the virus by mimicking its building blocks.
“These coronavirus polymerases are sloppy and they get fooled, so the inhibitor gets incorporated many times and the virus can no longer replicate,” Götte explained.
He said the evidence from his group, along with previously published studies in animal and cell culture models, means that remdesivir can be classified as a “direct-acting antiviral” against SARS-CoV-2, a term first used to describe newer classes of antivirals that interfere with specific steps of the hepatitis C virus (HCV) life cycle.
He said the discovery of that direct action reinforces the promise of clinical trials for remdesivir in COVID-19 patients, which are already underway around the world.
While Götte said the evidence justifies clinical trials, he cautioned that the results obtained in the lab cannot be used to predict how the drug will work with people.
“We’ve got to be patient and wait for the results of the randomized clinical trials,” said Götte, whose research was funded by the Canadian Institutes of Health Research, Alberta’s Major Innovation Fund and Gilead Sciences, which manufactures remdesivir.
Collaboration a cause for hope
The Götte lab previously worked on human immunodeficiency virus (HIV) and HCV, but a couple of years ago switched to focus on viruses with the highest epidemic potential. The World Health Organization (WHO) issued its list of the top pathogens likely to cause severe outbreaks, including Ebola, Lassa and coronaviruses, in 2015.
“In that sense we were prepared because my lab specializes in viral polymerases,” said Götte, adding that his next step will be to use his lab’s tools to evaluate other promising antivirals.
He is optimistic that the unprecedented amount of research going on worldwide and the high level of co-operation between researchers will lead to the discovery of one or more effective treatments for COVID-19.
“We are desperate, but we still have to keep the bar high for anything that we put into clinical trials,” he said.
Remdesivir is one of several drugs being fast-tracked into trials by the World Health Organization, comparing potential treatments in hospitalized COVID-19 patients in a dozen countries, including Canada. Götte said we can expect results from important clinical trials as early as April or May.
Götte said it is disappointing that antivirals discovered at the time of the severe acute respiratory syndrome (SARS) outbreak of 2003—which might have been effective against COVID-19 too—were never translated into widely available treatments, largely because of the huge cost involved in developing new drugs.
“This time around it’s obvious that we have to cross the finish line,” he said.
“Ten billion dollars, it seems a lot, a huge amount,” Götte said. “But in the context of this pandemic and the costs associated with this pandemic, it’s nothing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Gilead is Testing Inahalable Remdesivir, as a Possible Replacement for the Intravenous Form of the Drugon June 23, 2020 at 7:24 am
Gilead, the California-based pharmaceutical company that makes remdesivir, said it will start testing an inhaled form of its experimental COVID-19 therapy. Currently, patients can only receive the ...
- India's Cipla to price remdesivir version for COVID-19 under $66on June 23, 2020 at 4:32 am
Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said. Cipla and ...
- Gilead to Begin Human Trials for the Inhaled Version of Coronavirus Drug Remdesiviron June 22, 2020 at 3:00 pm
Gilead Sciences will begin human trials for an inhaled version of its antiviral drug remdesivir in August, the biotech company said Monday. Remdesivir, which was granted an emergency use authorization ...
- Gilead Sciences to start clinical trials of inhaled remdesivir for COVID-19on June 22, 2020 at 12:21 pm
Gilead Sciences plans to start clinical trials for an inhaled version of the antiviral remdesivir for the treatment of COVID-19, company officials said Monday.
- Inhaled Remdesivir May Allow COVID-19 Patients to Be Treated at Homeon June 22, 2020 at 9:55 am
An inhaled version of the antiviral drug remdesivir will soon be tested outside a hospital setting, Gilead Sciences announced Monday. Remdesivir, which is made by Gilead, is now being used to treat ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- BRIEF-FDA Says Request To Update Instructions For Use Of Abbott's Sars-CoV-2 IgG Assay Run On Architect I & Alinity I Systems Is Grantedon June 23, 2020 at 1:28 pm
June 23 (Reuters) - U.S. FDA: * FDA IN LETTER DATED JUNE 22 SAYS REQUEST TO UPDATE INSTRUCTIONS FOR USE OF ABBOTT'S SARS-COV-2 IGG ASSAY RUN ON ARCHITECT I & ALINITY I SYSTEMS IS GRANTED Source text: ...
- Single-dose Israeli vaccine candidate protective against SARS-CoV-2on June 22, 2020 at 10:27 pm
Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus ...
- Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serumon June 22, 2020 at 8:41 pm
One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum ...
- PreveCeutical to develop CBD Sol-Gel nasal spray for SARS-CoV-2 Infectionon June 22, 2020 at 3:39 pm
(OTCQB:PRVCF) has contracted UniQuest to apply the cannabinoid sol-gel technology for nasal spray formulation to be used as a potential treatment for COVID-19 caused by SARS-CoV- ...
- Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United Stateson June 22, 2020 at 11:49 am
Detection of SARS-CoV-2 infections to date has relied heavily on RT-PCR testing. However, limited test availability, high false-negative rates, and the existence of asymptomatic or sub-clinical ...